Kensuke Matsuda, Akira Honda, Shunya Arai, Hiroaki Maki, Kumi Nakazaki, Mineo Kurokawa (Hematol., Tokyo Univ., Tokyo, Japan)
Session information
Oral Session
Oral Session 2-14A GVHD: Clinic
Sat. Oct 13, 2018 4:00 PM - 5:00 PM No.14 (Osaka International Convention Center, 8F 801-2)
Chair: Yoshihiro Inamoto (National Cancer Center Hospital, Japan)
Keiko Fukunaga, Kazuhiro Ikegame, Katsuji Kaida, Takayuki Inoue, Satoshi Yoshihara, Kyoko Yoshihara, Yuko Osugi, Hiroya Tamaki, Masaya Okada, Hiroyasu Ogawa, Yoshihiro Fujimori (Hematology, Hyogo College of Medicine, Nishinomiya, Japan)
Souichi Shiratori, Hideki Goto, Junichi Sugita, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Eiko Hayase, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima (Department of Hematology, Hokkaido University Hospital, Sapporo, Japan)
Chikako Ohwada1, Emiko Sakaida1, Aiko Igarashi2, Noriko Doki2, Takehiko Mori3, Jun Kato3, Heiwa Kanamori4, Masatsugu Tanaka4, Shin Fujisawa5, Eriko Ogusa5, Masako Toyosaki6, Yasuyuki Aoyama6, Yoshinobu Kanda7, Hideki Nakasone7, Maki Hagihara8, Hiroaki Shimizu9, Seiko Kato10, Reiko Watanabe11, Katsuhiro Shono12, Rika Sakai13, Takeshi Saito14, Kensuke Usuki15, Chiaki Nakaseko16, Shinichiro Okamoto3,17 (1.Department of Hematology, Chiba University Hospital, 2.Hematology Division, Tokyo Metropolitan Cancer, 3.Division of Hematology, Keio University School of Medicine, 4.Department of Hematology, Kanagawa Cancer Center, 5.Department of Hematology, Yokohama City University Medical Center, 6.Division of Hematology/Oncology, Tokai University School of Medicine, 7.Division of Hematology, Saitama Medical Center, Jichi Medical University, 8.Department of Hematology and Clinical Immunology, Yokohama City University, 9.Department of Hematology, Gunma University School of Medicine, 10.Department of Hematology, The Institute of Medical Science, Tokyo University, 11.Department of Hematology, Saitama Medical Center, Saitama Medical University, 12.Division of Hematology, Chiba Aoba Municipal Hospital, 13.Kanagawa Cancer Center Department of Medical Oncology, 14.Division of Clinical Oncology/Hematology, Jikei University, 15.Division of Hematology, NTT Medical Center Tokyo, 16.Department of Hematology, International University of Health and Welfare, 17.Kanto Study Group for Cell Therapy (KSGCT))
Goichi Yoshimoto1, Yasuo Mori1, Akihiko Numata1, Koji Kato1, Takahiro Maeda2, Katsuto Takenaka1, Toshihiro Miyamoto1, Koichi Akashi1,2 (1.Hematology, Oncology and Cardiovascular medicine, Kyushu University Hospital, Fukuoka, 2.Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka)
Hiroyuki Muranushi1, Takero Shindo1, Masakatsu Hishizawa1, Masahito Tokunaga2, Atsushi Wake3, Nobuaki Nakano2, Tetsuya Eto4, Michihiro Hidaka5, Kaname Miyashita6, Toshihiro Miyamoto7, Takahiro Fukuda8, Tatsuo Ichinohe9, Yoshiko Atsuta10, Koji Kato7 (1.Department of Hematology and Oncology, Kyoto University, Kyoto, Japan, 2.Imamura General Hospital, Kagoshima, Japan, 3.Toranomon Hospital, Tokyo, Japan, 4.Hamanomachi Hospital, Fukuoka, Japan, 5.National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, 6.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 7.Kyushu University Hospital, Fukuoka, Japan, 8.National Cancer Center Hospital, Tokyo, Japan, 9.Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, 10.Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan)